Search Results
Your search for ,twO matches 12001 pages
Showing 7901 - 7950Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients With NSCLC and M1a Disease?
Analysis of a large non–small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis. Findings from the study were published by Dai et al in the Journal of Thoracic Oncology. Lung cancer is...
FDA Accepts New Drug Application, Grants Priority Review of Rucaparib for the Treatment of Advanced BRCA-Mutant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has accepted Clovis Oncology’s New Drug Application (NDA) for accelerated approval of rucaparib and granted Priority Review status to the application with a Prescription Drug User Fee Act date of February 23, 2017. Rucaparib is an...
Hypofractionated Radiotherapy: Balancing Benefits vs Risks in Men With Localized Prostate Cancer
Radiation for prostate cancer typically requires 40 to 45 daily treatments, given over 8 to 9 weeks. Long fractionation schemes are chosen for most cancers, because they allow for tumor killing while reducing the potential for injury to normal tissue. However, the radiobiology of prostate cancer...
Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer
In a phase III noninferiority trial (NRG Oncology RTOG 0415) reported in the Journal of Clinical Oncology, W. Robert Lee, MD, MS, Med, of Duke University Medical Center, and colleagues found that hypofractionated radiotherapy was not inferior to conventional radiotherapy in disease-free survival...
Melanoma MicroRNA Trafficking May Control Tumor Primary Niche Formation
Researchers at Tel Aviv University (TAU) may have unraveled the metastatic mechanism of melanoma. According to a paper published by Dror et al in Nature Cell Biology, scientists discovered that before spreading to other organs, a melanoma tumor sends out tiny vesicles containing molecules of...
Influence of Patients’ Side-Effect Expectations on Outcome of Endocrine Treatment for Breast Cancer
A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer found that the number and seriousness of side effects they experienced were influenced by their expectations. The study, published by Nestoriuc et al in Annals of Oncology, found that women...
Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy
Lucio Crinò, MD, of the University Medical School of Perugia, Italy, and colleagues found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib...
Nivolumab in Recurrent Small Cell Lung Cancer
In the phase I/II CheckMate 032 study, nivolumab (Opdivo) alone and with ipilimumab (Yervoy) demonstrated activity in patients with small cell lung cancer (SCLC) progressing after at least one previous platinum regimen, as reported in The Lancet Oncology by Antonia et al. Study Details In the SCLC...
Helen F. Graham Cancer Center and The Wistar Institute Partner to Expand Research in Gene Editing
To accelerate breakthrough cancer research in the human genome, the Gene Editing Institute at Christiana Care’s Helen F. Graham Cancer Center & Research Institute has entered into an agreement with The Wistar Institute. The agreement expands the historic partnership between the Graham Cancer...
Moffitt Cancer Center Receives Two NCI Grants to Further Prostate Cancer, Biomarker Research
Moffitt Cancer Center researchers recently received two National Cancer Institute (NCI) grants to further research in two areas of study: bone metastasis in prostate cancer and imaging biomarkers for early cancers. Moffitt Cancer Center researchers David Basanta, PhD, and Conor Lynch, PhD, have ...
FDA Approves Extended-Release Granisetron Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) has approved an extended-release version of granisetron (Sustol) for the prevention of chemotherapy-induced nausea and vomiting, according to a news release by Heron Therapeutics, the drug’s manufacturer. Granisetron is an extended-release, injectable...
Schwartz Center for Compassionate Healthcare Launches New Education and Training Programs
The Schwartz Center for Compassionate Healthcare recently announced the launch of two comprehensive educational offerings informed by the Compassionate, Collaborative Care—“The Triple C”—Framework, a new interdisciplinary model focused on improving quality and outcomes. The new educational...
Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer
As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...
A Complete Guide to Breast Surgery and Reconstruction
BookmarkTitle: Breast Cancer Surgery and Reconstruction: What’s Right for YouAuthor: Patricia Anstett, with photography by Kathleen GalliganPublisher: Rowman & LittlefieldPublication date: June 2, 2016Price: $35.00; hardcover, 224 pages Over the past 2 decades, we have seen tremendous...
Surgical Oncologist Quan P. Ly, MD, FACS, Flees From Vietnam and Finds a Home at the University of Nebraska
After the Vietnam War, close to a million refugees, known as “boat people,” fled Vietnam, hazarding the open ocean on dangerously overloaded vessels. The term “boat people” is often used generically to refer to all the Vietnamese (about 2 million) who left their country by any means between 1975...
Six Perspectives on the Cancer Moonshot Goal of Making 10 Years of Progress in 5 Years
The Cancer Moonshot initiative is bringing together scientists, oncologists, patient advocates, and representatives of the biopharmaceutical industry with renewed collaborative focus and the ambitious objective of consolidating 10 years of cancer research in 5 years. Achieving this outcome will...
Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated
The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer. HRT is used to treat...
Understanding Double-Hit Lymphomas and Optimizing Management
Double-hit lymphomas are a challenging subset of high-grade B-cell lymphomas, previously characterized histologically as diffuse large B-cell lymphoma or B-cell lymphoma unclassifiable with intermediate features between diffuse large B-cell lymphoma and Burkitt lymphoma. Expert guidance in their...
ASCO’s 2016 Quality Training Program: Meet the First International Participant From Greece
Launched in 2014, ASCO’s Quality Training Program was developed to prepare oncology providers to design, implement, and lead successful quality-improvement activities in their practices. It is a 6-month program that includes a structured and facilitated improvement project selected by each...
GADOLIN and the Perplexing Role of Obinutuzumab in the Treatment of B-Cell Malignancies
After several dose-finding phase I and II studies in a variety of B-cell malignancies, the potential clinical role of the newer anti-CD20 monoclonal antibody obinutuzumab (Gazyva) remained unclear. These early trials tested low and high doses as well as weekly and every-3-week schedules of...
Phase III Trial Shows Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Laurie H. Sehn, MD, Chair, British Columbia Cancer Agency Lymphoma Tumor Group, and Clinical Associate Professor at the University of British Columbia, Vancouver, and colleagues, found that adding the anti-CD20 antibody obinutuzumab...
Outcomes With Rituximab in DLBCL: Does Gender Matter?
For diffuse large B-cell lymphoma, does the dose of rituximab (Rituxan) matter? Are there patient characteristics that determine outcomes as well as the optimal dose? These questions were explored at the 2016 Pan Pacific Lymphoma Conference by Matthew A. Lunning, DO, Assistant Professor of...
AACR Holds Congressional Briefing to Reiterate Moonshot Goals and Plans
“We are in an era of unprecedented scientific opportunities in cancer research,” said Margaret Foti, PhD, MD (hc), Executive Officer, American Association for Cancer Research (AACR), as she introduced the Congressional briefing, “Seizing Today’s Opportunities to Accelerate Cancer Research.” “Thanks ...
Combination Obinutuzumab Regimen Active in Aggressive Diffuse Large B-Cell Lymphoma
In a small phase Ib/II study, 100% of patients with newly diagnosed diffuse large B-cell lymphoma evaluated thus far responded to treatment with obinutuzumab (Gazyva), lenalidomide (Revlimid), and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), investigators from the University of...
Novel Approaches Harness the Microenvironment Against Hodgkin Lymphoma
In the treatment of classical Hodgkin lymphoma, antibodies targeting programmed cell death protein 1 (PD-1) are just the beginning, according to Stephen M. Ansell, MD, PhD, Professor of Medicine and Chair of the Lymphoma Group at the Mayo Clinic, Rochester, Minnesota.1 Speaking at the 2016 Pan...
ASCO Guideline Addresses Controversial Areas in Adjuvant Therapy for Breast Cancer
ASCO has published an adaptation of the 2015 Cancer Care Ontario (CCO) clinical practice guideline on adjuvant chemotherapy for early-stage breast cancer.1 There were several areas of controversy that the guideline attempts to address. Should Anthracyclines Be Standard of Care? The guideline...
New Upfront Treatment Algorithm Emerges for Chronic Lymphocytic Leukemia
According to Susan M. O’Brien, MD, an expert in the treatment of chronic lymphocytic leukemia (CLL), novel agents and new data on patient subsets have led to a new upfront treatment algorithm for this malignancy. Speaking at the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, Dr. O’Brien...
Have You Received Your Immune Checkpoint Inhibitor Yet?
“Have you received your immune checkpoint inhibitor yet?” I suspect St. Peter may have started asking this question routinely at the Pearly Gates to Heaven. If St. Peter has not, I am sure most oncologists have. With extensive media coverage on the approval of nivolumab (Opdivo) and pembrolizumab...
Expert Point of View: Amir T. Fathi, MD
Amir T. Fathi, MD, an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School, Boston, commented on the INO-VATE ALL trial for The ASCO Post. “It has been a fairly exciting time for patients with acute lymphoblastic leukemia...
Study Links F12 and STC2 Genes to Breast Cancer Survival
Testing for the activity of two genes could help identify women who are at increased risk of dying from breast cancer, according to a new study of almost 2,000 patients. Women whose tumors had a specific pattern of activity in the F12 and STC2 genes were three times as likely to die within 10 years ...
Psychological Impact of Genetic Testing to Be Explored in Subset of NCI-MATCH Trial Patients
The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling, or COMET (EAQ152), to the NCI-MATCH (EAY131) trial already underway. Using feedback surveys before and after a patient undergoes tumor gene...
Study Finds Computers Surpass Pathologists in Predicting Lung Cancer Type, Severity
Computers can be trained to be more accurate than pathologists in assessing slides of lung cancer tissues, according to a new study by researchers at the Stanford University School of Medicine. The researchers found that a machine-learning approach to identifying critical disease-related features...
Bone Marrow–Derived Stem Cells May Offer Blood Transplant Recipients Better Quality of Life
A large, nationwide study published by Lee et al in the journal JAMA Oncology found that patients who received transplants of cells collected from a donor's bone marrow had better self-reported psychological well-being, experienced fewer symptoms of graft-vs-host disease (GVHD), and were more...
Pulmonary Complications in Adult Survivors of Childhood Cancer
A team of researchers from nine leading academic hospitals and research centers have published a paper in the journal Cancer that describes pulmonary outcomes among childhood cancer survivors. The study also evaluates the impact of complications such as asthma, chronic cough, emphysema, and...
Breast Density and Risk Factors May Be Useful for Tailoring Breast Cancer Screening for Older Women
A collaborative modeling study evaluating outcomes for various screening intervals for women over the age of 50 based on breast density and risk for breast cancer has found that average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density...
Leptomeningeal Metastases More Common in NSCLC With EGFR Mutations, May Be Responsive to Tyrosine Kinase Inhibitors
Leptomeningeal metastases, a serious complication in lung cancer patients, were found to be more prevalent in patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In a recent study of leptomeningeal metastases published by Li et al in...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, according to researchers at The University of Texas MD Anderson Cancer Center. Chen et al reported their findings in...
Report Tracks Cancer Trends by Race/Ethnicity in Los Angeles County for 37 Years
Prostate cancer and lung cancer have been the number 1 and 2 cancers among men. Stomach cancer, the third leading cause of cancer deaths worldwide, has been on a steady decline among Koreans and Japanese. Black men had the highest overall rates of cancer. Thyroid cancer has been on the rise, and...
New SSO, ASTRO, and ASCO Joint DCIS Consensus Guideline Could Curb Unnecessary Breast Surgery and Reduce Health System Costs
Three leading national cancer organizations have issued a consensus guideline for physicians treating women who have ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole breast irradiation. The new guideline has the potential to save many women from unnecessary...
Obesity on the Rise in Adults With a History of Cancer
A study at Columbia University's Mailman School of Public Health showed that obesity was more prevalent in patients with a history of cancer than in the general population, and survivors of colorectal and breast cancers were particularly affected. The study is among the first to compare rates of...
Needle Biopsies for Noninvasive Breast Cancer: Routine Analysis Wastes Millions
For patients with the most common type of noninvasive breast cancer, routine testing for estrogen and progesterone receptors in tissue taken at the first needle biopsy is both unnecessary and wasteful, according to results of a study led by Johns Hopkins pathologists. The results for people with...
Study Identifies Novel Treatment Resistance Mechanism in BRAF-Mutant Melanoma
A Massachusetts General Hospital (MGH) research team has identified an additional mechanism for resistance to targeted treatment for BRAF-mutant melanoma. Their findings, published by Shen et al in Nature Medicine, report that inactivating mutations in two genes responsible for regulating key...
New American Cancer Society Cancer Action Network Report Shows States Are Making Progress Implementing Policies to Reduce Toll of Cancer
Although a majority of states are still missing important opportunities to pass and implement legislative solutions proven to prevent and fight cancer, there is progress being made to move the nation closer to ending cancer as we know it, according to a report recently released by the American...
New Study Shows Breast Tumors May Evolve in Response to Hormone Therapy
Many breast tumors grow in response to female hormones, especially estrogen. Drugs that reduce estrogen levels in the body often are effective in reducing tumor size and preventing recurrence of the cancer. But some tumors become resistant to these therapies and continue to grow and spread. A new...
Similar Functional Outcomes Reported With Robot-Assisted Laparoscopic and Open Radical Retropubic Prostatectomy
Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar domain-specific quality-of-life or pathologic outcomes at 12 weeks in men with newly diagnosed, clinically localized prostate cancer, according to the results of a randomized phase III trial reported ...
FDA Approves Extended-Release Granisetron Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Heron Therapeutics, Inc, announced on August 10, 2016, that the U.S. Food and Drug Administration (FDA) has approved granisetron (Sustol) extended-release injection. Granisetron is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention ...
Insurance Status Impacts Survival, According to Two New Studies
Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found. The findings, published by Markt et al in Cancer, add to growing evidence that differences in health insurance status can affect...
Internationally Renowned Geneticist, Alfred George Knudson, MD, PhD, Dies
Considered a visionary in cancer research, Alfred George Knudson, MD, PhD, was internationally recognized for his “two-hit theory” of cancer causation, which explained the relationship between hereditary and nonhereditary cancer types, predicting the existence of tumor suppressor genes. Dr. Knudson ...
Final Results of METEOR Trial: Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma
As reported by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma...
A Ruby Anniversary
On July 16, 1975, at 26 years of age, after almost 6 months of observing a left epididymal mass slowly enlarge, with workup for epididymal tuberculosis, I finally underwent a left inguinal orchiectomy and resection of what proved to be a pure seminoma. A subsequent lymphangiogram was reported to...
